Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2011

Open Access 01.12.2011 | Case report

Primary malignant mixed müllerian tumor of the peritoneum a case report with review of the literature

verfasst von: Fisnik Kurshumliu, Helle Rung-Hansen, Vibeke Ravn Skovlund, Lumturije Gashi-Luci, Thomas Horn

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2011

Abstract

Malignant mixed Müllerian tumor is a rare malignancy of the genital tract and extremely uncommon in extragenital sites. This report describes a case of malignant mixed Müllerian tumor arising in the lower peritoneum of a 72-year-old female patient. The patient presented with ascites, lower abdominal mass and pleural effusion. The serum level of CA125 was elevated. At operation a diffuse carcinosis associated with tumor mass measuring 20 × 15 × 10 cm in the vesicouterine and Duglas' pouch were found. The uterus and the adnexa were unremarkable. Histopathology revealed a typical malignant mixed Müllerian tumor, heterologous type. The epithelial component was positive for cytokeratin 7 and vimentin whereas the mesenchymal component was positive for Vimentin, S100 and focally for CK7. The histogenesis of this tumor arising from the peritoneum is still speculative. Based on the previous reports and the immunohistochemical analysis of our case, we believe that this is a monoclonal tumor with carcinoma being the "precursor" element. Nevertheless, further molecular and genetic evidence is needed to support such a conclusion.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7819-9-17) contains supplementary material, which is available to authorized users.

Authors' contributions

FK prepared the manuscript and reviewed the literature. HRH provided the clinical data. VRH reviewed the slides, LGL reviewed the manuscript, TH reviewed the slides and supervised the preparation of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Background

Malignant mixed Müllerian tumor (MMMT) is a rare entity that arises from structures that are embryologically related to the Müllerian system [1, 2]. The usual location of MMMT is the female genital tract. Extragenital origin is extremely rare [35]. Histologically and by immunohistochemistry, the tumor exhibits both epithelial and mesenchymal components.
Since the first report in 1955 by Ober and Black [5], to our knowledge there have been only 30 well documented reports of extragenital malignant mixed Müllerian tumors [615]. This prompted us to report on a tumor with primary peritoneal location and to review the relevant existing literature.

Case Report

A 72-year-old woman, with unremarkable gynaecological history presented with chest pain and dyspnoea, increasing in intensity over the last three weeks. A chest X-ray showed pleural effusion and the subsequent fine needle aspiration cytology revealed malignant epithelial cells. The serum level of CA125 was 712 U/ml.
CT scan of abdomen and chest revealed ascites and pleural effusion but no tumor mass. Pelvic ultrasonography, however, revealed excrescences adjacent to the interior surface of the abdominal wall and tumor load in the lower part of abdomen. The uterus and the right ovary were described as normal; the left ovary was not visualised.
An ultrasound-guided biopsy from the tumor reported a carcinosarcoma (see later).
The patient underwent exploratory laparotomy. A widely spread peritoneal carcinosis and a tumor measuring 20 × 15 × 10 cm in the vesicouterine and Duglas' pouch were found.
Biopsy samples were taken from the tumor as well as from the serosa of the urinary bladder. Also, complete hysterectomy with partial omentectomy was performed. There was no suspicion of intrahepatic metastasis. Gallbladder, stomach, pancreas and appendix were unremarkable.
Histopathology was consistent with the diagnosis of a primary peritoneal malignant mixed Müllerian tumor given that the uterus and the adnexa were unremarkable.
Postoperatively, the patient underwent chemotherapy (Carboplatin in doses of 468 mg/360 mg every third week, as it was not felt that the patient was fit for more aggressive treatment). The disease progressed despite treatment and subsequent introduction of Treosulfan.
The patient passed away 12 months after diagnosis. No autopsy was performed.

Material and methods

Gross pathology

The tumor tissue submitted for pathology were fragmented, irregular tissue masses measuring altogether 16 × 12 × 4.5cm. All the fragments were tan-white, irregular fleshy masses with areas of necrosis and hemorrhage.
The uterus and the Fallopian tubes were unremarkable. The right and the left ovary were of normal dimensions. Numerous sections were taken from the tumor as well as from the uterus and adnexa.

Histology and Histochemistry

The tissue was fixed in 10% neutral buffered formalin (pH 7,0), routinely processed, and embedded in paraffin using standard methods. Four-micrometer sections were stained with hematoxylin and eosin, Periodic acid-Schiff (PAS) with diastase predigestion, and Alcian/PAS.

Immunohistochemistry

Formalin-fixed, paraffin-embedded tissue was stained with the peroxidase method using the EnVision visualisation system (Additional file 1).

Results

Histology and histochemistry

Most of the tumor tissue had the characteristics of poorly differentiated carcinoma (Figure 1). There was no squamous cell or glandular differentiation. The mesenchymal component was composed of sheets of undifferentiated spindle cells and areas of cartilage (Figure 2).
Numerous sections from the uterus and the adnexae showed no evidence of tumor.

Immunohistochemistry

Immunohistochemical staining for cytokeratin 7 decorated cells of the epithelial component and scattered cells within the mesenchymal component (Figure 3 and Figure 4). Vimentin was strongly positive in mesenchymal component and sporadicaly in the epithelial areas (Figure 5). Cytokeratin 20 and calretinin were negative in both epithelial and mesenchymal elements.

Discussion and the review of Literature

Malignant mixed Müllerian tumor (MMMT) is a highly aggressive tumor consisted of malignant epithelial and stromal cells. MMMTs were traditionally regarded as a subtype of uterine sarcomas or a mixture of true carcinoma and sarcoma, however several reports suggested a monoclonal origin of these tumors [13] Interestingly, molecular data published by Wada and co-workers [4] suggested that although most carcinosarcomas are combination tumors, some develop as collision tumors.
The morphology of the present tumor is consistent with malignant mixed Müllerian tumor. The epithelial component exhibited positivity for cytokeratin 7 and Vimentin and was negative for Cytokeratin 20. Moreover, the mesenchymal component was diffusely positive for Vimentin, focally for CK 7 and exhibited areas of heterologous malignant cartilage.
The primary peritoneal location and origin was confirmed after thorough gross and microscopic examination of the uterus and adnexae. Furthermore, absence of calretinin expression suggested that the tumor was of Müllerian rather than pure mesothelial origin [6]. A search of the literature revealed 30 previously reported cases of extragenital MMMT (Additional file 2) with the majority of the patients being in the postmenopausal age [519]. Twenty-two of the reported cases were of primary peritoneal origin and most of them arose in the pelvis [19]. Thirteen were heterologous type [19].
In the homologous type MMMT, mesothelioma would rightfully be considered as a possibility [6]. However, in this case a positive reaction of the cells to Calretinin would be expected [6]. Immunoreactivity of the epithelial cells to Cytokeratin 7 and negative reaction for cytokeratin 20 also points toward Müllerian origin. A theoretical possibility is of course the origin in endometriosis or endosalpingiosis. However, although impossible to rule out, the lack of demonstrable endometriosis associated with the patient's current tumor makes this hypothesis unlikely [16].
Several theories have emerged in the attempt to explain the biphasic appearance of the tumor, the most important of which are the "collision", "conversion" and the "combination" theory [1]. Sternberg et al. [20] was the first to suggest the conversion, stating that sarcomatous elements may develop from carcinoma. They described a case of metastatic heterologous type carcinosarcoma of the omentum with primary endometrial origin. There was no evidence of sarcoma component in the primary tumor. From that time onward, a number of cases with metachronous or synchronous gynaecologic carcinoma have been reported [11, 14, 16]. Masuda et al. [21] further supported the conversion theory with their study in which cell lines established from malignant mixed Müllerian tumors showed the ability of the epithelial tumor cells to transform into epithelial, mesenchymal or both types of differentiation in vitro, while the mesenchymal cells did not show similar capabilities.
MMMT has a poor prognosis with most of the patients following a rapidly fatal course regardless of the initial tumor stage [9]. A review done by Garamvoelgyi et al. [14] showed that most patients passed away within one year with median postoperative survival time being 14 months. Due to the rarity of the disease, limited data regarding the management of peritoneal MMMT exist. Treatment modalities include surgery, chemotherapy and irradiation with various survival outcomes. Ko et al. [19] reported on a patient that was treated with optimal tumor debulking and a combination of chemotherapy with Ifosfamide and Cisplatin, followed by pelvic irradiation. There were no signs of recurrence for 48 months and was the case with the longest disease-free survival in the reported literature.

Conclusion

Based on the ample evidence of the previous reports, and the immunohistochemical analysis of our case, we believe that this is a monoclonal tumor with the carcinoma being the "precursor" element. Nevertheless, further molecular and genetic evidence is needed to support such a conclusion.
Informed consent was obtained from the patient for publication of this case report and accompanying images.
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://​creativecommons.​org/​licenses/​by/​2.​0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors' contributions

FK prepared the manuscript and reviewed the literature. HRH provided the clinical data. VRH reviewed the slides, LGL reviewed the manuscript, TH reviewed the slides and supervised the preparation of the manuscript.

Competing interests

The authors declare that they have no competing interests.
Literatur
2.
Zurück zum Zitat Mayall F, Rutty K, Campbell F, Goddard H: p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology. 1994, 24 (3): 211-214. 10.1111/j.1365-2559.1994.tb00512.x.CrossRefPubMed Mayall F, Rutty K, Campbell F, Goddard H: p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology. 1994, 24 (3): 211-214. 10.1111/j.1365-2559.1994.tb00512.x.CrossRefPubMed
3.
Zurück zum Zitat Watanabe M, Shimizu K, Kato H, Imai H, Nakano H, Sugawa M, Shiraishi T: Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case. Gynecol Oncol. 2001, 82 (3): 563-567. 10.1006/gyno.2001.6307.CrossRefPubMed Watanabe M, Shimizu K, Kato H, Imai H, Nakano H, Sugawa M, Shiraishi T: Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case. Gynecol Oncol. 2001, 82 (3): 563-567. 10.1006/gyno.2001.6307.CrossRefPubMed
4.
Zurück zum Zitat Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, Haba T, Wakasa K, Shroyer KR, Tsujimoto M, Hongyo T, Nomura T, Murata Y: Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors Cancer Res. 1997, 57: 5379-5385. Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, Haba T, Wakasa K, Shroyer KR, Tsujimoto M, Hongyo T, Nomura T, Murata Y: Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors Cancer Res. 1997, 57: 5379-5385.
5.
Zurück zum Zitat Ober WB, Black MB: Neoplasms of the subcoelomic mesenchyme: report of two cases. Arch Pathol. 1955, 59: 698-705. Ober WB, Black MB: Neoplasms of the subcoelomic mesenchyme: report of two cases. Arch Pathol. 1955, 59: 698-705.
6.
Zurück zum Zitat Sumathi VP, Murnaghan M, Dobbs SP, McCluggage WG: Extragenital Müllerian carcinosarcoma arising from the peritoneum: report of two cases. Int J Gynecol Cancer. 2002, 12: 764-767. 10.1046/j.1525-1438.2002.01146.x.CrossRefPubMed Sumathi VP, Murnaghan M, Dobbs SP, McCluggage WG: Extragenital Müllerian carcinosarcoma arising from the peritoneum: report of two cases. Int J Gynecol Cancer. 2002, 12: 764-767. 10.1046/j.1525-1438.2002.01146.x.CrossRefPubMed
7.
Zurück zum Zitat Lauchlan SC: The secondary Müllerian system. Obstet Gynecol Surg. 1972, 27: 133-146. 10.1097/00006254-197203000-00001.CrossRef Lauchlan SC: The secondary Müllerian system. Obstet Gynecol Surg. 1972, 27: 133-146. 10.1097/00006254-197203000-00001.CrossRef
8.
Zurück zum Zitat Zelmanowicz A, Hildesheim A, Sherman ME, Sturgeon SR, Kurman RJ, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD, Brinton LA: Evidence for a common etiology for endometrial carcinomas and malignant mixed Müllerian tumors. Gynecol Oncol. 1998, 69: 253-257. 10.1006/gyno.1998.4941.CrossRefPubMed Zelmanowicz A, Hildesheim A, Sherman ME, Sturgeon SR, Kurman RJ, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD, Brinton LA: Evidence for a common etiology for endometrial carcinomas and malignant mixed Müllerian tumors. Gynecol Oncol. 1998, 69: 253-257. 10.1006/gyno.1998.4941.CrossRefPubMed
9.
Zurück zum Zitat Friedrich M, Villena-Heinsen C, Mink D, Bonkhoff H, Schmidt W: Carcinosarcoma, endometrial intraepithelial carcinoma and endometriosis after tamoxifen therapy in breast cancer. Eur J Obstet Gynecol. 1999, 82: 85-87. 10.1016/S0301-2115(98)00166-3.CrossRef Friedrich M, Villena-Heinsen C, Mink D, Bonkhoff H, Schmidt W: Carcinosarcoma, endometrial intraepithelial carcinoma and endometriosis after tamoxifen therapy in breast cancer. Eur J Obstet Gynecol. 1999, 82: 85-87. 10.1016/S0301-2115(98)00166-3.CrossRef
10.
Zurück zum Zitat Nascimento MC, Choo PS, Bligh J, Obermair A: Primary peritoneal malignant mixed Müllerian tumor (MMMT): a case report. Cancer Therapy. 2004, 2: 571-574. Nascimento MC, Choo PS, Bligh J, Obermair A: Primary peritoneal malignant mixed Müllerian tumor (MMMT): a case report. Cancer Therapy. 2004, 2: 571-574.
11.
Zurück zum Zitat Shen DH, Khoo US, Xue WC, Ngan HYS, Wang JL, Liu VWS, Chan YK, Cheung ANY: Primary peritoneal malignant mixed Müllerian tumors: a clinicopathologic, immunohistochemical and genetic study. Cancer. 2001, 91: 1052-1060. 10.1002/1097-0142(20010301)91:5<1052::AID-CNCR1097>3.0.CO;2-A.CrossRefPubMed Shen DH, Khoo US, Xue WC, Ngan HYS, Wang JL, Liu VWS, Chan YK, Cheung ANY: Primary peritoneal malignant mixed Müllerian tumors: a clinicopathologic, immunohistochemical and genetic study. Cancer. 2001, 91: 1052-1060. 10.1002/1097-0142(20010301)91:5<1052::AID-CNCR1097>3.0.CO;2-A.CrossRefPubMed
12.
Zurück zum Zitat Shintaku M, Matsumoto T: Primary Müllerian carcinosarcoma of the retroperitoneum: report of a case. International J Gynecol Pathol. 2001, 20: 191-195. 10.1097/00004347-200104000-00013.CrossRef Shintaku M, Matsumoto T: Primary Müllerian carcinosarcoma of the retroperitoneum: report of a case. International J Gynecol Pathol. 2001, 20: 191-195. 10.1097/00004347-200104000-00013.CrossRef
13.
Zurück zum Zitat Ibanez-Manlapaz IG, McCoy D, Vincent V, Ule UJ: Malignant mixed Müllerian tumor of the extra-genital coelomic epithelium: report of two cases. Pathology Oncology Research. 1997, 3: 130-134. 10.1007/BF02907808.CrossRefPubMed Ibanez-Manlapaz IG, McCoy D, Vincent V, Ule UJ: Malignant mixed Müllerian tumor of the extra-genital coelomic epithelium: report of two cases. Pathology Oncology Research. 1997, 3: 130-134. 10.1007/BF02907808.CrossRefPubMed
14.
Zurück zum Zitat Garamvoelgyi E, Guillou I, Gebhard S, Salmeron M, Seematter RJ, Hadji MH: Primary malignant mixed Müllerian tumor (metaplastic carcinoma) of the female peritoneum. Cancer. 1994, 74: 854-863. 10.1002/1097-0142(19940801)74:3<854::AID-CNCR2820740311>3.0.CO;2-R.CrossRefPubMed Garamvoelgyi E, Guillou I, Gebhard S, Salmeron M, Seematter RJ, Hadji MH: Primary malignant mixed Müllerian tumor (metaplastic carcinoma) of the female peritoneum. Cancer. 1994, 74: 854-863. 10.1002/1097-0142(19940801)74:3<854::AID-CNCR2820740311>3.0.CO;2-R.CrossRefPubMed
15.
Zurück zum Zitat Choong SYM, Scurry JP, Planner RS, Grant PT: Extrauterine malignant mixed Müllerian tumor of primary peritoneal origin. Pathology. 1994, 26: 497-498. 10.1080/00313029400169272.CrossRefPubMed Choong SYM, Scurry JP, Planner RS, Grant PT: Extrauterine malignant mixed Müllerian tumor of primary peritoneal origin. Pathology. 1994, 26: 497-498. 10.1080/00313029400169272.CrossRefPubMed
16.
Zurück zum Zitat Garde JR, Jones MA, McAfee R, Tarraza HM: Extragenital malignant mixed Müllerian tumor. Gynaecol Oncol. 1991, 43: 186-190. 10.1016/0090-8258(91)90070-L.CrossRef Garde JR, Jones MA, McAfee R, Tarraza HM: Extragenital malignant mixed Müllerian tumor. Gynaecol Oncol. 1991, 43: 186-190. 10.1016/0090-8258(91)90070-L.CrossRef
17.
Zurück zum Zitat Weisz-Carrington P, Bigelow B, Schinella RA: Extragenital mixed heterologous tumor of Müllerian type arising in the cecal peritoneum: report of a case. Dis Colon Rectum. 1977, 20 (4): 329-333. 10.1007/BF02586432.CrossRefPubMed Weisz-Carrington P, Bigelow B, Schinella RA: Extragenital mixed heterologous tumor of Müllerian type arising in the cecal peritoneum: report of a case. Dis Colon Rectum. 1977, 20 (4): 329-333. 10.1007/BF02586432.CrossRefPubMed
18.
Zurück zum Zitat Hasiuk AS, Petersen RO, Hanjani P, Griffin TD: Extragenital malignant mixed Müllerian tumor: case report and review of the literature. Am J Clin Pathol. 1984, 81: 102-105.PubMed Hasiuk AS, Petersen RO, Hanjani P, Griffin TD: Extragenital malignant mixed Müllerian tumor: case report and review of the literature. Am J Clin Pathol. 1984, 81: 102-105.PubMed
19.
Zurück zum Zitat Ko ML, Jeng CJ, Huang SH, Shen J, Tzeng CR, Chen SC: Primary peritoneal carcinosarcoma (malignant mixed Müllerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature. Acta Oncologica. 2005, 44 (7): 756-760. 10.1080/02841860500252016.CrossRefPubMed Ko ML, Jeng CJ, Huang SH, Shen J, Tzeng CR, Chen SC: Primary peritoneal carcinosarcoma (malignant mixed Müllerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature. Acta Oncologica. 2005, 44 (7): 756-760. 10.1080/02841860500252016.CrossRefPubMed
20.
Zurück zum Zitat Sternberg WH, Clark WH, Smith RC: Malignant mixed Müllerian tumor (malignant mixed mesodermal tumor) of the uterus: a study of 21 cases. Cancer. 1954, 7: 704-724. 10.1002/1097-0142(195407)7:4<704::AID-CNCR2820070411>3.0.CO;2-D.CrossRefPubMed Sternberg WH, Clark WH, Smith RC: Malignant mixed Müllerian tumor (malignant mixed mesodermal tumor) of the uterus: a study of 21 cases. Cancer. 1954, 7: 704-724. 10.1002/1097-0142(195407)7:4<704::AID-CNCR2820070411>3.0.CO;2-D.CrossRefPubMed
21.
Zurück zum Zitat Masuda A, Takeda A, Fukami H, Yamada C, Matsuyama M: Characteristics of cell lines established from mixed mesodermal tumor of the human ovary: carcinomatous cells are changeable to sarcomatous cells. Cancer. 1987, 60: 2969-2703. 10.1002/1097-0142(19871201)60:11<2696::AID-CNCR2820601120>3.0.CO;2-R.CrossRef Masuda A, Takeda A, Fukami H, Yamada C, Matsuyama M: Characteristics of cell lines established from mixed mesodermal tumor of the human ovary: carcinomatous cells are changeable to sarcomatous cells. Cancer. 1987, 60: 2969-2703. 10.1002/1097-0142(19871201)60:11<2696::AID-CNCR2820601120>3.0.CO;2-R.CrossRef
Metadaten
Titel
Primary malignant mixed müllerian tumor of the peritoneum a case report with review of the literature
verfasst von
Fisnik Kurshumliu
Helle Rung-Hansen
Vibeke Ravn Skovlund
Lumturije Gashi-Luci
Thomas Horn
Publikationsdatum
01.12.2011
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2011
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-9-17

Weitere Artikel der Ausgabe 1/2011

World Journal of Surgical Oncology 1/2011 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.